Drug Profile
Finafloxacin - MerLion Pharmaceuticals
Alternative Names: AL-60371; BY-377; EXE 844; EXE 844b; Finafloxacin hydrochloride; Gastrochinolon; Gastroquinolone; XtoroLatest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator Bayer
- Developer Alcon; MerLion Pharmaceuticals
- Class Antibacterials; Eye disorder therapies; Fluoroquinolones; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Otitis externa
- Phase II Helicobacter infections; Pyelonephritis; Urinary tract infections
- No development reported Bacterial infections; Otitis media; Respiratory tract infections
Most Recent Events
- 29 Nov 2022 No development reported - Phase-II for Urinary tract infections in Germany (PO)
- 28 Dec 2018 No recent reports of development identified for phase-I development in Otitis-media(In children, In infants) in USA (Otic, Suspension)
- 31 Jul 2018 MerLion regains global rights to finafloxacin after termination of licensing deal between Alcon and MerLion